Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.150-158, 2005 |
||
Title: Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome | ||
Author: I.E., PANAGIOTOU ; E.N., BROUNTZOS ; D.A., KELEKIS ; M.A., PAPATHANASIOU ; D.I., BAFALOUKOS ; | ||
Abstract: The aim of our study was to analyze prognostic factors, effect of
treatment and survival outcome of a contemporary cohort of
melanoma patients with cerebral metastases and eventually propose
new recommendations regarding therapy.
Sixty four patients with melanoma brain metastases were treated in
our department within a 15-year period. We performed a
retrospective analysis of their survival with respect to the type
of treatment instituted. Four groups were formed according to
treatment: Group A patients treated with surgery followed by
radiotherapy; group B temozolomide as first-line treatment and
radiotherapy after cerebral disease progression; group C
radiotherapy alone; group D supportive care only.
Patients’ characteristics influenced the selection of treatment
modality: Group A (7.8 %) patients with a single brain metastasis
(p=0.001) and controlled extra-cranial disease (p<0.0001), while
Group D (21.8 %) patients with ulcerated primary lesions (p=0.010)
and uncontrolled extra-cranial disease (p<0.0001). Only group B
(26.6 %) and C (43.7 %) patients with similar characteristics
including more than one brain lesion. Median overall survival was
3 months. In univariate analysis, median survival for groups A, B,
C and D was 12, 5, 3 and 2 months, respectively (p<0.0001). The
survival difference between the surgery and non-surgery groups was
statistically significant (p=0.0011). Patients treated with
supportive care had the worse prognosis (p<0.0001). A survival
benefit for patients receiving first-line treatment with
temozolomide, as compared to those receiving radiotherapy alone
was noted (p=0.0267). In multivariate survival analysis, the
number of brain lesions (p=0.0138), the absence of uncontrolled
extra-cranial disease (p=0.00221) and the type of treatment for
the cerebral disease (p=0.0053) remained significant independent
survival predictors.
Patients’ characteristics remain a critical factor for treatment
selection. The number of brain metastases, the extent of disease
and the type of treatment represent independent survival
predictors. Melanoma patients with a single brain metastasis and
controlled extra-cranial disease gain a survival benefit, if
surgically treated. Including temozolomide in the first-line
treatment of melanoma patients with brain metastases who would
have been treated with radiotherapy alone, might present a
promising future direction affecting the length of survival.
|
||
Keywords: melanoma, brain metastases, survival, treatment, temozolomide | ||
Year: 2005, Volume: 52, Issue: | Page From: 150, Page To: 158 | |
|
download file |
|